Systemic Therapy for Melanoma: ASCO Rapid Recommendation Update
- Guideline Contact
- [email protected]
- Publication Date
- 03-Jun-22
- Date of Last Evidence Search
- 2022
- Countries of Application
- United States
- Languages
- English
- Authors
- ASCO (US)
Ovarian Neoplasms (C04.588.322.455); Neoplasm Recurrence; Local (C04.697.655); Neoplasm Metastasis (C04.697.650)
Drug Therapy; Combination (E02.319.310); Meta-Analysis as Topic (E05.581.500.501); Drug Therapy (E02.319)
Consensus Development Conference (V03.300); Consensus (F01.829.316.068); Myelodysplastic Syndromes (C15.378.190.625)
Neuroendocrine Carcinoma, Gastroenteropancreatic neuroendocrine tumor, Phase 3 Clinical Trial, Phase 4 Clinical Trial, Randomized Controlled Trial, Guideline, Systematic Review, Quality Assessment, Adult, Octreotide, 177Lu-Dotatate, 90y-Dotatate
Drug Therapy (E02.319); Antineoplastic Agents (D27.505.954.248); Drug Therapy; Combination (E02.319.310); Prostatic Neoplasms (C04.588.945.440.770)